The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine

Yuri Fujioka,Hideto Ueki,Ruhan A,Akari Sasajima,Takumi Tomono,Masami Ukawa,Haruya Yagi,Shinji Sakuma,Koichi Kitagawa,Toshiro Shirakawa

DOI: https://doi.org/10.3390/ijms25115997

IF: 5.6

2024-05-31

International Journal of Molecular Sciences

Abstract:Cancer immunotherapy using antigen-pulsed dendritic cells can induce strong cellular immune responses by priming cytotoxic T lymphocytes. In this study, we pulsed tumor cell lysates with VP-R8, a cell-penetrating D-octaarginine-linked co-polymer of N-vinylacetamide and acrylic acid (PNVA-co-AA), into the DC2.4 murine dendritic cell line to improve antigen uptake and then determined the anti-tumor effect in tumor-bearing mice. DC2.4 cells were pulsed with the cell lysate of EL4, a murine lymphoma cell line, and VP-R8 to generate the DC2.4 vaccine. For the in vivo study, DC2.4 cells pulsed with EL4 lysate and VP-R8 were subcutaneously injected into the inguinal lymph node to investigate the anti-tumor effect against EL4 and EL4-specific T cell immune responses. VP-R8 significantly improved antigen uptake into DC2.4 compared to conventional keyhole limpet hemocyanin (p < 0.05). The expression of MHC class I, MHC class II, and CD86 in DC2.4 cells significantly increased after pulsing tumor lysates with VP-R8 compared to other treatments (p < 0.05). The intra-lymph node injection of DC2.4 pulsed with both VP-R8 and EL4 lysate significantly decreased tumor growth compared to DC2.4 pulsed with KLH and lysates (p < 0.05) and induced tumor-infiltrating CD8T cells. The DC2.4 vaccine also remarkably increased the population of IFN-gamma-producing T cells and CTL activity against EL4 cells. In conclusion, we demonstrated that VP-R8 markedly enhances the efficiency of dendritic cell-based vaccines in priming robust anti-tumor immunity, suggesting its potential as a beneficial additive for dendritic cell-based immunotherapy.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper aims to address the issue of improving the efficiency of dendritic cell (DC) vaccines in cancer immunotherapy. The researchers used a cell-penetrating N-vinylpyrrolidone and acrylic acid copolymer linked with D-octarginine (VP-R8) to enhance DC's ability to uptake and present tumor antigens. By introducing VP-R8 together with tumor cell lysate into the mouse DC2.4 cell line, they observed a significant increase in antigen uptake and enhanced expression of MHC class I, MHC class II, and CD86 molecules on the surface of DCs. Furthermore, VP-R8-treated DC2.4 cells, when injected into the inguinal lymph nodes in vivo, were able to significantly inhibit tumor growth, increase CD8+ T cell infiltration, and induce the production of IFN-γ-producing T cells and cytotoxic T lymphocyte (CTL) activity. These results suggest that VP-R8 can serve as a beneficial additive to enhance the effectiveness of dendritic cell therapy and holds promise for cancer immunotherapy.

The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors

Enhanced Therapeutic Efficacy Of Tumor Rna-Pulsed Dendritic Cells After Genetic Modification With Lymphotactin

Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Polyethyleneimine modification of aluminum hydroxide nanoparticle enhances antigen transportation and cross-presentation of dendritic cells.

A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants As a General Strategy for Cancer Immunotherapy.

[Antitumor Immune Responses Induced by Idiotype-Pulsed Dendritic Cells with Cell-Penetrating Peptide Vaccination in Vivo].

Dendritic Cell Immunotherapy Induces Anti-Tumor Effect in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen

Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100

Dual Adjuvant-Loaded Peptide Antigen Self-Assembly Potentiates Dendritic Cell-Mediated Tumor Immunotherapy

Co-transfection Gene Delivery of Dendritic Cells Induced Effective Lymph Node Targeting and Anti-tumor Vaccination

[Controlled Live Dendritic Cell Vaccine Mediates Potent Antitumor Immune Responses].

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen

Dendritic Cells Based Immunotherapy

Prophylactic Dendritic Cell Vaccination Controls Pancreatic Cancer Growth in a Mouse Model.

A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy

Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma